ArticleClinical, cosmetic and investigational dermatology2023
Controlled-Release
Article in Clinical, cosmetic and investigational dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Development of Oral pH-Sensitive Eudragit L100-FunctionalizedACS omega · 2026Article
- Green-Engineered PEI/PVA-Functionalized Silk Fibroin Nanoparticles for Heat-Stable Delivery ofACS omega · 2025Article
- PEGylated Silk Fibroin Nanoparticles for Oral Antibiotic Delivery: Insights into Drug-Carrier Interactions and Process Greenness.ACS omega · 2025Article
- Sustainable Silk-Based Particulate Systems for the Controlled Release of Pharmaceuticals and Bioactive Agents in Wound Healing and Skin Regeneration.International journal of molecular sciences · 2024Review
- Development of pH-responsive Eudragit S100-functionalized silk fibroin nanoparticles as a prospective drug delivery system.PloS one · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Purpose: This study explored the potentials of WT loaded fibroin microparticles (FMPs-WT) as a novel anti-aging cosmeceutical product. Methods: The WT flower was firstly extracted by maceration with methanol, ethanol 60%, and ethanol 96%, and its chemical compositions and total polyphenol content were investigated. Then, the FMPs-WT were developed by desolvation method and physicochemically characterized. Finally, the product antioxidant activities were in-vitro determined using DPPH assay. Results: The optimal WT extract was the ethanol 60% extract, which contains polyphenols, alkaloids, flavonoids, saponins, glycosides, and organic acids; with a total polyphenol content of 46.47 ± 2.32 mg GAE/g plant powder. The FMPs-WT were successfully formulated, with a distinct silk-II polymorph; varied sizes of 0.592 to 9.820 µm, depending on the fibroin concentrations and the WT extraction solvent; high entrapment efficiencies of >65%; and sustained-release patterns of polyphenol in pH 7.4 for >6 h. Regarding the antioxidant activity, the pure WT flower extracts possessed high scavenging actions with IC Conclusion: The FMPs-WT could be further investigated to become a potential anti-aging cosmeceutical product in the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.